SAN DIEGO and WASHINGTON, June 10 /PRNewswire/ -- OREXIGEN(TM) Therapeutics, Inc., a privately held clinical-stage neuroscience company developing a novel strategic approach to the treatment of obesity, today announced that the company’s lead program, Contrave(TM), a combination of two centrally-acting medications, demonstrated greater sustained weight loss in a six month Phase II clinical study than either monotherapies or placebo. The findings showed that in the subjects using Contrave more than half of those who completed the trial demonstrated 5% weight loss over 24 weeks, 18% demonstrated 10% weight loss, and the trajectory of these weight loss curves showed no evidence of a plateau. These top line Phase II data for Contrave were presented at the 66th annual Scientific Sessions of the American Diabetes Association (ADA) in Washington, DC.
